These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470 [TBL] [Abstract][Full Text] [Related]
7. Biobanking: An Important Resource for Precision Medicine in Glioblastoma. Tan SY; Sandanaraj E; Tang C; Ang BT Adv Exp Med Biol; 2016; 951():47-56. PubMed ID: 27837553 [TBL] [Abstract][Full Text] [Related]
8. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care. Habib A; Pease M; Kodavali CV; Amankulor N; Zinn PO J Neurooncol; 2021 Jan; 151(2):103-112. PubMed ID: 33394264 [TBL] [Abstract][Full Text] [Related]
9. [Targeted therapy in glioblastoma: update and perspectives]. Idbaih A; Duran-Peña A; Alentorn A Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421 [TBL] [Abstract][Full Text] [Related]
10. Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations. Kunos CA; Galanis E; Buchsbaum J; Shi Q; Strauss LC; Coleman CN; Ahmed MM J Neurooncol; 2017 Sep; 134(3):551-557. PubMed ID: 28560665 [TBL] [Abstract][Full Text] [Related]
11. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model. Daher A; de Groot J Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369 [TBL] [Abstract][Full Text] [Related]
12. Management of glioblastoma: State of the art and future directions. Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924 [TBL] [Abstract][Full Text] [Related]
13. A novel treatment for glioblastoma: integrin inhibition. Chamberlain MC; Cloughsey T; Reardon DA; Wen PY Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214 [TBL] [Abstract][Full Text] [Related]
14. One size should not fit all: advancing toward personalized glioblastoma therapy. Reardon DA; Ligon KL; Chiocca EA; Wen PY Discov Med; 2015 Jun; 19(107):471-7. PubMed ID: 26175405 [TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms of Treatment Resistance in Glioblastoma. Ou A; Yung WKA; Majd N Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396284 [TBL] [Abstract][Full Text] [Related]
16. Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. Noch EK; Ramakrishna R; Magge R World Neurosurg; 2018 Aug; 116():505-517. PubMed ID: 30049045 [TBL] [Abstract][Full Text] [Related]
17. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma. Londhe VY; Date V Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in therapy for glioblastoma. Clarke J; Butowski N; Chang S Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224 [TBL] [Abstract][Full Text] [Related]
19. Recent advances in targeted therapy for glioblastoma. Mittal S; Pradhan S; Srivastava T Expert Rev Neurother; 2015; 15(8):935-46. PubMed ID: 26118735 [TBL] [Abstract][Full Text] [Related]
20. Molecular and genetic pathways in gliomas: the future of personalized therapeutics. Grant R; Kolb L; Moliterno J CNS Oncol; 2014 Mar; 3(2):123-36. PubMed ID: 25055018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]